NeuroRX

, Volume 2, Issue 3, pp 447–464

The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies

Authors

    • Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical ScienceBMC A10
  • Natalija Popovic
    • Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical ScienceBMC A10
  • Patrik Brundin
    • Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical ScienceBMC A10
Article

DOI: 10.1602/neurorx.2.3.447

Cite this article as:
Li, J.Y., Popovic, N. & Brundin, P. Neurotherapeutics (2005) 2: 447. doi:10.1602/neurorx.2.3.447

Summary

Huntington’s disease (HD) is a genetic neurodegenerative disorder. Since identification of the disease-causing gene in 1993, a number of genetically modified animal models of HD have been generated. The first transgenic mouse models, R6/1 and R6/2 lines, were established 8 years ago. The R6/2 mice have been the best characterized and the most widely used model to study pathogenesis of HD and therapeutic interventions. In the present review, we especially focus on the characteristics of R6 transgenic mouse models and, in greater detail, describe the different therapeutic strategies that have been tested in these mice. We also, at the end, critically assess the relevance of the HD mouse models compared with the human disease and discuss how they can be best used in the future.

Key Words

Huntington’s diseasetherapytransgenic miceR6/2neurodegenerative diseases
Download to read the full article text

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2005